Symbols / FATE
FATE Chart
About
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 185.14M |
| Enterprise Value | 50.70M | Income | -156.09M | Sales | 7.14M |
| Book/sh | 2.03 | Cash/sh | 1.87 | Dividend Yield | — |
| Payout | 0.00% | Employees | 181 | IPO | — |
| P/E | — | Forward P/E | -1.42 | PEG | — |
| P/S | 25.94 | P/B | 0.79 | P/C | — |
| EV/EBITDA | -0.35 | EV/Sales | 7.10 | Quick Ratio | 7.74 |
| Current Ratio | 7.87 | Debt/Eq | 33.86 | LT Debt/Eq | — |
| EPS (ttm) | -1.33 | EPS next Y | -1.13 | EPS Growth | — |
| Revenue Growth | -43.40% | Earnings | 2026-03-04 | ROA | -23.85% |
| ROE | -52.35% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -19.95% | Profit Margin | 0.00% | Shs Outstand | 115.35M |
| Shs Float | 100.71M | Short Float | 11.28% | Short Ratio | 6.58 |
| Short Interest | — | 52W High | 1.94 | 52W Low | 0.66 |
| Beta | 2.25 | Avg Volume | 1.52M | Volume | 1.40M |
| Target Price | $4.94 | Recom | Buy | Prev Close | $1.62 |
| Price | $1.60 | Change | -0.93% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.94
Mean price target
2. Current target
$1.61
Latest analyst target
3. DCF / Fair value
$-9.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.61
Low
$2.00
High
$8.00
Mean
$4.94
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-31 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-10-27 | up | Wedbush | Neutral → Outperform | $7 |
| 2025-10-27 | reit | Needham | Hold → Hold | — |
| 2025-08-13 | main | Wells Fargo | Equal-Weight → Equal-Weight | $3 |
| 2025-06-12 | reit | Needham | Hold → Hold | — |
| 2025-05-14 | main | Barclays | Overweight → Overweight | $2 |
| 2025-05-14 | main | Baird | Neutral → Neutral | $4 |
| 2025-05-14 | reit | Needham | Hold → Hold | — |
| 2025-03-06 | main | Stifel | Hold → Hold | $3 |
| 2025-03-06 | reit | Wedbush | Neutral → Neutral | $5 |
| 2025-03-06 | main | Wells Fargo | Equal-Weight → Equal-Weight | $4 |
| 2025-03-06 | reit | Needham | Hold → Hold | — |
| 2024-11-19 | reit | Needham | — → Hold | — |
| 2024-11-13 | reit | Needham | — → Hold | — |
| 2024-08-22 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-08-14 | reit | Needham | — → Hold | — |
| 2024-06-17 | up | Piper Sandler | Neutral → Overweight | $6 |
| 2024-05-16 | main | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-05-10 | main | Canaccord Genuity | Buy → Buy | $9 |
| 2024-05-10 | main | BMO Capital | Market Perform → Market Perform | $6 |
- Fate Therapeutics (FATE) to Release Earnings on Wednesday - MarketBeat Wed, 25 Feb 2026 09
- Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Yahoo Finance Sun, 21 Dec 2025 08
- $FATE stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 29 Oct 2025 07
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire ue, 03 Feb 2026 08
- 4 events this week will dictate the fate of markets through year-end - Business Insider ue, 18 Nov 2025 08
- FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation - GuruFocus ue, 17 Feb 2026 12
- Fate Therapeutics: Recent Update Met With Selling, But Positives Exist - Seeking Alpha Fri, 29 Aug 2025 07
- Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates - Nasdaq hu, 13 Nov 2025 08
- Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average - What's Next? - MarketBeat ue, 10 Feb 2026 08
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 - Quiver Quantitative ue, 25 Nov 2025 08
- Needham Reiterates Fate Therapeutics (FATE) Hold Recommendation - Nasdaq Mon, 27 Oct 2025 07
- 'Big Short' investor Michael Burry defends his calls for a stock market bubble and predicts a 'Netscape fate' for OpenAI - Business Insider Mon, 08 Dec 2025 08
- Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - Yahoo Finance ue, 15 Jul 2025 07
- Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire ue, 25 Nov 2025 08
- Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat Sun, 01 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 100000 | — | — | Stock Award(Grant) at price 0.00 per share. | TAHL CINDY R | Officer | — | 2026-01-15 00:00:00 | D |
| 1 | 335000 | — | — | Stock Award(Grant) at price 0.00 per share. | VALAMEHR BAHRAM | Chief Executive Officer | — | 2026-01-15 00:00:00 | D |
| 2 | 25000 | — | — | Stock Award(Grant) at price 0.00 per share. | ADAWI KAMAL | Chief Financial Officer | — | 2026-01-15 00:00:00 | D |
| 3 | 10589 | 11275.0 | — | Sale at price 1.06 per share. | TAHL CINDY R | Officer | — | 2026-01-09 00:00:00 | D |
| 4 | 5190 | 5557.0 | — | Sale at price 1.07 per share. | VALAMEHR BAHRAM | Chief Executive Officer | — | 2026-01-09 00:00:00 | D |
| 5 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | ADAWI KAMAL | Chief Financial Officer | — | 2025-10-20 00:00:00 | D |
| 6 | 9037 | 9573.0 | — | Sale at price 1.06 per share. | TAHL CINDY R | Officer | — | 2025-08-04 00:00:00 | D |
| 7 | 14466 | 15396.0 | — | Sale at price 1.06 per share. | VALAMEHR BAHRAM | Chief Executive Officer | — | 2025-08-04 00:00:00 | D |
| 8 | 70000 | — | — | Stock Award(Grant) at price 0.00 per share. | TAHL CINDY R | Officer | — | 2025-01-15 00:00:00 | D |
| 9 | 65000 | — | — | Stock Award(Grant) at price 0.00 per share. | BRESSI JEROME CHARLES | Officer | — | 2025-01-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -162.66M | -174.74M | -314.94M | -214.68M |
| TotalUnusualItems | -13.92M | 2.52M | 20.31M | 3.53M |
| TotalUnusualItemsExcludingGoodwill | -13.92M | 2.52M | 20.31M | 3.53M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -186.26M | -160.93M | -281.72M | -212.15M |
| ReconciledDepreciation | 18.96M | 18.28M | 13.76M | 5.85M |
| EBITDA | -176.58M | -172.23M | -294.63M | -211.14M |
| EBIT | -195.54M | -190.51M | -308.39M | -216.99M |
| NetInterestIncome | 17.29M | 17.19M | 5.84M | 1.31M |
| InterestExpense | 0.00 | |||
| InterestIncome | 17.29M | 17.19M | 5.84M | 1.31M |
| NormalizedIncome | -172.34M | -163.44M | -302.03M | -215.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -186.26M | -160.93M | -281.72M | -212.15M |
| TotalExpenses | 209.17M | 254.04M | 404.69M | 272.84M |
| TotalOperatingIncomeAsReported | -210.28M | -190.51M | -308.39M | -216.99M |
| DilutedAverageShares | 113.69M | 98.41M | 96.83M | 94.75M |
| BasicAverageShares | 113.69M | 98.41M | 96.83M | 94.75M |
| DilutedEPS | -1.64 | -1.64 | -2.91 | -2.24 |
| BasicEPS | -1.64 | -1.64 | -2.91 | -2.24 |
| DilutedNIAvailtoComStockholders | -186.26M | -160.93M | -281.72M | -212.15M |
| NetIncomeCommonStockholders | -186.26M | -160.93M | -281.72M | -212.15M |
| NetIncome | -186.26M | -160.93M | -281.72M | -212.15M |
| NetIncomeIncludingNoncontrollingInterests | -186.26M | -160.93M | -281.72M | -212.15M |
| NetIncomeContinuousOperations | -186.26M | -160.93M | -281.72M | -212.15M |
| PretaxIncome | -186.26M | -160.93M | -281.72M | -212.15M |
| OtherIncomeExpense | -8.01M | 12.40M | 20.82M | 3.53M |
| OtherNonOperatingIncomeExpenses | 5.91M | 9.88M | 516.00K | |
| SpecialIncomeCharges | -14.74M | 0.00 | ||
| ImpairmentOfCapitalAssets | 14.74M | 0.00 | ||
| GainOnSaleOfSecurity | 819.00K | 2.52M | 20.31M | 3.53M |
| NetNonOperatingInterestIncomeExpense | 17.29M | 17.19M | 5.84M | 1.31M |
| InterestExpenseNonOperating | 0.00 | |||
| InterestIncomeNonOperating | 17.29M | 17.19M | 5.84M | 1.31M |
| OperatingIncome | -195.54M | -190.51M | -308.39M | -216.99M |
| OperatingExpense | 209.17M | 254.04M | 404.69M | 272.84M |
| ResearchAndDevelopment | 135.00M | 172.60M | 320.45M | 215.52M |
| SellingGeneralAndAdministration | 74.17M | 81.45M | 84.23M | 57.32M |
| GeneralAndAdministrativeExpense | 74.17M | 81.45M | 84.23M | 57.32M |
| OtherGandA | 74.17M | 81.45M | 84.23M | 57.32M |
| TotalRevenue | 13.63M | 63.53M | 96.30M | 55.85M |
| OperatingRevenue | 13.63M | 63.53M | 96.30M | 55.85M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 113.93M | 98.63M | 97.29M | 95.73M |
| ShareIssued | 113.93M | 98.63M | 97.29M | 95.73M |
| TotalDebt | 85.27M | 103.54M | 109.34M | 114.82M |
| TangibleBookValue | 318.72M | 368.41M | 483.94M | 678.84M |
| InvestedCapital | 318.72M | 368.41M | 483.94M | 678.84M |
| WorkingCapital | 253.39M | 292.45M | 388.02M | 552.13M |
| NetTangibleAssets | 318.73M | 368.42M | 483.94M | 678.84M |
| CapitalLeaseObligations | 85.27M | 103.54M | 109.34M | 114.82M |
| CommonStockEquity | 318.72M | 368.41M | 483.94M | 678.84M |
| PreferredStockEquity | 3.00K | 3.00K | 3.00K | 3.00K |
| TotalCapitalization | 318.73M | 368.42M | 483.94M | 678.84M |
| TotalEquityGrossMinorityInterest | 318.73M | 368.42M | 483.94M | 678.84M |
| StockholdersEquity | 318.73M | 368.42M | 483.94M | 678.84M |
| GainsLossesNotAffectingRetainedEarnings | 268.00K | 15.00K | -1.85M | -762.00K |
| OtherEquityAdjustments | 268.00K | 15.00K | -1.85M | -762.00K |
| RetainedEarnings | -1.40B | -1.21B | -1.05B | -769.08M |
| AdditionalPaidInCapital | 1.72B | 1.58B | 1.54B | 1.45B |
| CapitalStock | 117.00K | 102.00K | 100.00K | 99.00K |
| CommonStock | 114.00K | 99.00K | 97.00K | 96.00K |
| PreferredStock | 3.00K | 3.00K | 3.00K | 3.00K |
| TotalLiabilitiesNetMinorityInterest | 121.97M | 137.80M | 221.62M | 242.62M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 83.45M | 98.71M | 107.57M | 161.33M |
| OtherNonCurrentLiabilities | 5.07M | 800.00K | ||
| DerivativeProductLiabilities | 527.00K | 1.35M | 3.86M | 24.17M |
| NonCurrentDeferredLiabilities | 0.00 | 27.12M | ||
| NonCurrentDeferredRevenue | 0.00 | 27.12M | ||
| LongTermDebtAndCapitalLeaseObligation | 77.85M | 97.36M | 103.71M | 109.24M |
| LongTermCapitalLeaseObligation | 77.85M | 97.36M | 103.71M | 109.24M |
| CurrentLiabilities | 38.52M | 39.09M | 114.05M | 81.28M |
| OtherCurrentLiabilities | 4.00M | 3.20M | ||
| CurrentDeferredLiabilities | 393.00K | 685.00K | 42.23M | 21.48M |
| CurrentDeferredRevenue | 393.00K | 685.00K | 42.23M | 21.48M |
| CurrentDebtAndCapitalLeaseObligation | 7.42M | 6.18M | 5.63M | 5.58M |
| CurrentCapitalLeaseObligation | 7.42M | 6.18M | 5.63M | 5.58M |
| PayablesAndAccruedExpenses | 30.71M | 32.23M | 62.20M | 51.02M |
| CurrentAccruedExpenses | 21.35M | 27.51M | 53.93M | 42.41M |
| Payables | 9.37M | 4.72M | 8.27M | 8.61M |
| AccountsPayable | 9.37M | 4.72M | 8.27M | 8.61M |
| TotalAssets | 440.69M | 506.22M | 705.56M | 921.46M |
| TotalNonCurrentAssets | 148.78M | 174.68M | 203.49M | 288.04M |
| OtherNonCurrentAssets | 10.24M | 15.19M | 15.26M | 15.26M |
| NonCurrentAccountsReceivable | 7.20M | 9.87M | ||
| InvestmentsAndAdvances | 27.66M | 980.00K | 4.94M | 100.66M |
| InvestmentinFinancialAssets | 27.66M | 980.00K | 4.94M | 100.66M |
| AvailableForSaleSecurities | 27.66M | 980.00K | 4.94M | 100.66M |
| NetPPE | 110.89M | 158.51M | 176.09M | 162.25M |
| AccumulatedDepreciation | -35.14M | -47.63M | -30.38M | -16.95M |
| GrossPPE | 146.03M | 206.14M | 206.47M | 179.19M |
| Leases | 59.48M | 59.04M | 56.78M | 52.95M |
| ConstructionInProgress | 0.00 | |||
| OtherProperties | 35.90M | 78.85M | 77.35M | 50.25M |
| MachineryFurnitureEquipment | 4.14M | 6.57M | 6.27M | 5.28M |
| BuildingsAndImprovements | 105.99M | 120.71M | 122.85M | 123.67M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 291.91M | 331.54M | 502.07M | 633.41M |
| OtherCurrentAssets | 9.30M | 14.54M | 27.37M | 8.83M |
| PrepaidAssets | 8.83M | |||
| Receivables | 3.54M | 1.83M | 38.48M | 8.68M |
| AccountsReceivable | 3.54M | 1.83M | 38.48M | 8.68M |
| CashCashEquivalentsAndShortTermInvestments | 279.07M | 315.18M | 436.23M | 615.91M |
| OtherShortTermInvestments | 243.01M | 273.31M | 374.89M | 482.33M |
| CashAndCashEquivalents | 36.06M | 41.87M | 61.33M | 133.58M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -123.60M | -138.42M | -283.77M | -213.57M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 74.53M | 0.00 | 0.00 | 411.74M |
| CapitalExpenditure | -730.00K | -6.15M | -35.57M | -50.70M |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 46.28M | 57.05M | 76.56M | 148.81M |
| BeginningCashPosition | 57.05M | 76.56M | 148.81M | 182.57M |
| ChangesInCash | -10.76M | -19.51M | -72.25M | -33.76M |
| FinancingCashFlow | 99.89M | 85.00K | 9.21M | 453.13M |
| CashFlowFromContinuingFinancingActivities | 99.89M | 85.00K | 9.21M | 453.13M |
| NetOtherFinancingCharges | 5.07M | |||
| ProceedsFromStockOptionExercised | 20.29M | 85.00K | 9.21M | 41.39M |
| NetCommonStockIssuance | 74.53M | 0.00 | 0.00 | 411.74M |
| CommonStockIssuance | 74.53M | 0.00 | 0.00 | 411.74M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| InvestingCashFlow | 12.22M | 112.67M | 166.75M | -324.02M |
| CashFlowFromContinuingInvestingActivities | 12.22M | 112.67M | 166.75M | -324.02M |
| NetInvestmentPurchaseAndSale | 12.95M | 118.82M | 202.32M | -273.32M |
| SaleOfInvestment | 330.70M | 477.63M | 607.11M | 694.84M |
| PurchaseOfInvestment | -317.75M | -358.81M | -404.80M | -968.16M |
| NetPPEPurchaseAndSale | -730.00K | -6.15M | -35.57M | -50.70M |
| PurchaseOfPPE | -730.00K | -6.15M | -35.57M | -50.70M |
| OperatingCashFlow | -122.87M | -132.26M | -248.21M | -162.87M |
| CashFlowFromContinuingOperatingActivities | -122.87M | -132.26M | -248.21M | -162.87M |
| ChangeInWorkingCapital | -1.96M | 19.18M | -34.71M | 2.10M |
| ChangeInOtherWorkingCapital | -4.42M | -1.41M | -828.00K | 2.40M |
| ChangeInPayablesAndAccruedExpense | -1.66M | -28.94M | 14.25M | 5.91M |
| ChangeInPrepaidAssets | 5.24M | 12.88M | -18.33M | -3.05M |
| ChangeInReceivables | -1.11M | 36.65M | -29.80M | -3.16M |
| ChangesInAccountReceivables | -1.11M | 36.65M | -29.80M | -3.16M |
| OtherNonCashItems | -1.71M | -40.86M | -24.01M | -18.10M |
| StockBasedCompensation | 41.50M | 43.46M | 78.73M | 54.36M |
| AssetImpairmentCharge | 14.74M | 0.00 | ||
| AmortizationOfSecurities | -9.08M | -11.40M | -256.00K | 5.07M |
| DepreciationAmortizationDepletion | 18.96M | 18.28M | 13.76M | 5.85M |
| DepreciationAndAmortization | 18.96M | 18.28M | 13.76M | 5.85M |
| OperatingGainsLosses | 942.00K | |||
| GainLossOnSaleOfPPE | 942.00K | 0.00 | ||
| NetIncomeFromContinuingOperations | -186.26M | -160.93M | -281.72M | -212.15M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for FATE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|